Agah Ramtin, the Executive Chairman and Chief Medical Officer of RenovoRx, Inc., has acquired 50,000 shares of the company's common stock. The transaction, which took place on November 16, 2026, is significant as it reflects Ramtin's confidence in the future of RenovoRx. This acquisition may also influence how investors perceive the company's potential growth.

RenovoRx, Inc. operates within the surgical and medical instruments industry, specifically categorized under the SIC description of Surgical & Medical Instruments & Apparatus. The company is based in Mountain View, California, and is known for its innovative approaches in the medical field. This filing is part of a series of recent transactions by Ramtin, indicating a consistent pattern of investment in his own company.

According to the recent SEC filing, Ramtin's latest purchase was made at a weighted average price of $0.9297 per share, with prices ranging from $0.925 to $0.9299. Following this transaction, Ramtin now holds a total of 848,460 shares of RenovoRx. The filing noted, "Reflects open market purchases of the Issuer's securities," highlighting the nature of this acquisition.

This transaction may affect stakeholders, including other investors and market analysts, as insider purchases often signal confidence in a company's future performance. Ramtin's active involvement and investment in RenovoRx could bolster investor sentiment and potentially attract more attention to the company's offerings.

The filing does not say what happens next.